Free NIH Hybrid Meeting on Rehab Research Open Now
Published Date: 9/24/2025
Notice
Summary
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is hosting a hybrid meeting on May 4, 2026, about medical rehabilitation research. Anyone interested can join in person or online, share ideas, or even speak at the meeting. This is a great chance for scientists, patients, and the public to get involved and help shape future research without any registration fees.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Free public hybrid meeting May 4, 2026
The National Advisory Board on Medical Rehabilitation Research will hold a hybrid public meeting on May 4, 2026, from 10:00 a.m. to 5:00 p.m. You can attend in person at 6710 B Rockledge Drive, Bethesda, MD 20817 or watch online via the NIH Videocast (https://videocast.nih.gov/). Registration is not required to attend.
You may file written comments
Any interested person may file written comments with the committee by forwarding a statement to the Contact Person. Statements should include the name, address, telephone number, and, when applicable, the business or professional affiliation of the sender.
Apply to present oral comments (10-day notice)
If you want to present oral comments, you must notify the Contact Person at least 10 days before the meeting and submit a letter of intent, a brief description of your organization (if any), and a short description of the oral presentation. Only one representative per organization may present, and accepted presentations may be limited to five minutes; both printed and electronic copies are requested for the record.
Request special assistance or accommodation
Individuals who plan to attend in person or view the virtual meeting and need special assistance or other reasonable accommodation should notify the Contact Person listed in the notice in advance of the meeting.
On-campus security rules for visitors
Visitors attending the meeting on campus will be subject to NIH security procedures: vehicles (including taxis and shuttles) will be inspected, and on-campus visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and state the purpose of their visit, per the notice and the NIH visitor-information link.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-18462, International Product Change-Priority Mail Express International, Priority Mail International & First-Class Package International Service Agreements
The Postal Service is updating its list of special international shipping deals for Priority Mail Express International, Priority Mail International, and First-Class Package International Service. This means businesses and customers using these services might see new contract options soon. These changes aim to keep international shipping smooth and competitive, with no immediate price hikes announced.
Next: 2025-18465, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Partially Closed Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a two-day virtual meeting on January 26-27, 2026. The first day is open to the public and will share updates and scientific talks, while the second day is closed to review grant applications confidentially. Researchers and the public can join or send comments, with no cost to attend and easy online access.